Extraskeletal myxoid chondrosarcoma – Diagnostics – Overview of Information and Clinical Research

Extraskeletal myxoid chondrosarcoma (EMC) is a very rare cancer that requires specialized testing to confirm the diagnosis and determine the best treatment approach. Because this disease can develop anywhere in the body and may not cause symptoms for months, understanding when to seek medical evaluation and what diagnostic procedures to expect is essential for patients and their families.

Introduction: Who Should Undergo Diagnostics

Diagnosing extraskeletal myxoid chondrosarcoma starts with recognizing warning signs that should prompt a visit to a healthcare provider. Because EMC (a rare form of soft tissue cancer) grows slowly, symptoms often develop gradually over weeks or months rather than appearing suddenly. The most important reason to seek medical attention is the presence of a lump or swelling that persists for more than two weeks without going away on its own.^[2]

The most common symptom that brings people to their doctor is a soft tissue mass that can be felt under the skin. This lump is often located in the upper parts of the arms or legs, though it can appear anywhere in the body.^[2] Importantly, this swelling is frequently accompanied by pain and tenderness in the affected area, which may worsen over time. Some people describe the lump as resembling a bruise in appearance, though it does not heal like a typical bruise would.^[2]

If you notice a lump near a joint, you may experience restricted movement or difficulty using that limb normally. This happens because the growing tumor can press against surrounding structures and limit your range of motion.^[2] Another concerning sign is feeling exhausted all the time without an obvious cause. This persistent fatigue, combined with a lump that does not disappear, warrants immediate medical evaluation.^[2]

⚠️ Important

Because extraskeletal myxoid chondrosarcoma grows slowly, its symptoms can be easy to dismiss at first. Many people wait months before seeking help, thinking a lump will go away on its own. However, any lump or swelling that persists for two weeks or more should be evaluated by a doctor, especially if accompanied by pain, tenderness, or unexplained fatigue. Early diagnosis can significantly impact treatment options.

Adults in middle age, particularly those between 40 and 75 years old, should be especially attentive to these symptoms, as this is the age group most commonly affected by EMC. The average age at diagnosis is around 51 years.^[1] Men should be particularly vigilant, as this disease affects males twice as often as females.^[2] While EMC can develop in anyone, some individuals with certain inherited genetic disorders have a higher risk and may benefit from more regular monitoring, though this is quite rare.^[4]

Diagnostic Methods

When you visit a healthcare provider with concerns about a possible soft tissue tumor, the diagnostic process typically follows a systematic approach designed to confirm the presence of EMC and distinguish it from other conditions. This process involves several steps, starting with basic examinations and progressing to more specialized tests as needed.

Physical Examination

The first step in diagnosing extraskeletal myxoid chondrosarcoma is a thorough physical examination. A specialist will carefully look at and feel the lump or swelling to assess its size, texture, location, and whether it causes pain when touched.^[2] During this examination, the doctor will also check how the lump relates to surrounding structures like muscles, bones, and joints. They may ask you questions about when you first noticed the lump, whether it has grown, and what symptoms you have experienced. This hands-on assessment provides important initial information but cannot definitively confirm EMC, which is why imaging and tissue sampling are necessary next steps.

Imaging Tests

After the physical examination, your doctor will likely order various imaging tests to create detailed pictures of the inside of your body. These scans help determine the size and location of the tumor and whether it has spread to other areas. Several types of imaging may be used, depending on your specific situation.^[2]

Ultrasound uses sound waves to create images and is often one of the first imaging tests performed. It can help distinguish a solid mass from a fluid-filled cyst and is particularly useful for examining soft tissue lumps close to the skin surface.^[2] X-rays may be taken to check whether the tumor has affected nearby bones, though EMC primarily involves soft tissues rather than bone itself.^[2]

More detailed imaging typically includes CT scans (computed tomography), which use X-rays taken from multiple angles to create cross-sectional images of your body. CT scans are particularly helpful for examining the chest to check for lung metastases, as the lungs are a common site where EMC may spread.^[6] MRI scans (magnetic resonance imaging) use powerful magnets and radio waves to produce extremely detailed images of soft tissues. MRI is often considered the best imaging method for evaluating EMC because it clearly shows the tumor’s relationship to surrounding muscles, nerves, and blood vessels.^[2]

PET scans (positron emission tomography) may be ordered in some cases to detect areas of high metabolic activity that might indicate cancer spread to distant parts of the body.^[2] In one documented case, enhanced spiral CT combined with Cone Beam CT was used to carefully examine the extent of a gingival EMC tumor, showing how advanced imaging can reveal detailed information about tumor characteristics.^[6]

Biopsy: The Definitive Test

While imaging tests can suggest the presence of a tumor, only a biopsy (the removal and examination of tissue) can definitively confirm a diagnosis of extraskeletal myxoid chondrosarcoma. During a biopsy, a doctor removes a sample of the tumor tissue, which is then examined under a microscope by a specialist called a pathologist.^[2]

The pathologist looks for specific features that characterize EMC. Under the microscope, EMC tumor cells typically appear round or slightly elongated with a uniform shape and size. These cells are surrounded by an abundant myxoid matrix (a jelly-like substance) and are often arranged in patterns described as ribbons, cords, or small nests.^[6] The tumor tissue usually has a multinodular pattern, meaning it is divided into multiple sections separated by fibrous bands.^[6]

Immunohistochemistry

After examining the tissue structure, the pathologist performs specialized tests called immunohistochemistry (IHC), which use antibodies to detect specific proteins in the tumor cells. This helps distinguish EMC from other tumors that may look similar under a microscope. In EMC, tumor cells typically test positive for a protein called vimentin. They may also show variable staining for S-100 protein, though less than 20 percent of EMC cases show this marker strongly.^[4]^[6] The cells are usually negative for other markers like calponin, SMA (smooth muscle actin), and SOX10.^[6]

Molecular Testing

The most definitive diagnostic test for EMC is molecular genetic testing, specifically fluorescent in situ hybridization (FISH). This specialized laboratory technique detects specific genetic changes that are characteristic of EMC. The disease is defined by rearrangements involving the NR4A3 gene located on chromosome 9.^[4]^[6]

In most cases of EMC, the NR4A3 gene becomes fused with another gene, most commonly EWSR1 (on chromosome 22) or TAF15 (on chromosome 17).^[4]^[7] When FISH testing shows positive results for NR4A3 rearrangement, this strongly confirms the diagnosis of EMC and helps distinguish it from other soft tissue tumors that may appear similar.^[6] This genetic signature is so specific to EMC that it has become an essential part of the diagnostic process, particularly in cases where the microscopic appearance alone might be ambiguous.

⚠️ Important

The diagnosis of extraskeletal myxoid chondrosarcoma requires a combination of different tests working together. A physical exam and imaging alone cannot confirm EMC. Only a biopsy examined by an experienced pathologist, combined with immunohistochemistry and molecular genetic testing (FISH), can provide a definitive diagnosis. This comprehensive approach is necessary because EMC is extremely rare and can be confused with other conditions.

Differentiating EMC from Similar Conditions

One of the challenges in diagnosing extraskeletal myxoid chondrosarcoma is that several other conditions can appear similar on imaging or even under the microscope. The diagnostic process must carefully distinguish EMC from these other tumors. Because EMC cells do not express specific tumor marker proteins that would make identification straightforward, the combination of microscopic appearance, immunohistochemistry results, and molecular testing becomes crucial.^[4]

Despite its name suggesting cartilage involvement, EMC actually does not show convincing evidence of cartilaginous differentiation. Recent research has even proposed that these tumors may have a neuroectodermic origin rather than a cartilage-related one.^[6] This understanding has evolved over time and highlights why comprehensive testing is needed rather than relying on the tumor’s name or initial appearance alone.

Diagnostics for Clinical Trial Qualification

For patients interested in participating in clinical trials testing new treatments for extraskeletal myxoid chondrosarcoma, additional diagnostic procedures and documentation are typically required. Clinical trials have specific criteria for enrollment, and confirming these criteria through standardized testing ensures that study results are reliable and meaningful.

Pathological Confirmation Requirements

Clinical trials studying EMC require thorough pathological confirmation of the diagnosis before a patient can enroll. This typically means having the original biopsy slides and tissue samples reviewed by experienced pathologists at the trial center to verify that the diagnosis is correct. The review must confirm the characteristic microscopic features of EMC, including the myxoid matrix, the arrangement of tumor cells, and the multinodular pattern.^[6]

In addition to standard microscopic examination, clinical trials usually require documented molecular confirmation of the NR4A3 gene rearrangement through FISH testing or similar molecular techniques.^[6]^[9] This genetic confirmation is particularly important because it definitively distinguishes EMC from other soft tissue sarcomas that might initially appear similar. Trials may also request information about which specific gene fusion is present (such as EWSR1-NR4A3 or TAF15-NR4A3), as different fusion types might respond differently to treatments being studied.^[7]

Disease Staging and Extent Assessment

Before enrolling in a clinical trial, patients typically undergo comprehensive imaging to determine the stage and extent of their disease. This staging process determines whether the cancer is localized (confined to one area) or has spread to distant sites. For EMC, the most common site of distant spread is the lungs, so chest CT scans are a standard part of staging workup.^[6]

Clinical trials often have specific requirements about disease stage. Some trials may only accept patients with newly diagnosed localized disease that can be removed by surgery, while others specifically focus on patients with advanced disease that has spread to distant organs. One example is a clinical trial studying radiation therapy with or without chemotherapy before surgery in patients with newly diagnosed non-rhabdomyosarcoma soft tissue sarcomas (which includes EMC) that can eventually be removed by surgery.^[10] This trial requires careful imaging to confirm that the tumor is potentially resectable despite its size or location.

Baseline Tumor Measurements

Clinical trials need precise baseline measurements of all tumor sites to evaluate whether the treatment being studied is effective. This typically involves detailed imaging with CT or MRI scans performed according to specific protocols. The largest dimension of the primary tumor must be documented, as well as measurements of any metastatic lesions if present.^[9] These baseline measurements will be compared to follow-up scans performed during and after treatment to determine if tumors have shrunk, stayed the same size, or grown.

Performance Status and Laboratory Tests

Clinical trials typically require documentation of a patient’s overall health status and organ function through various laboratory tests. Blood tests may include complete blood counts, kidney function tests, liver function tests, and other markers to ensure that a patient can safely tolerate the treatment being studied. These tests help researchers determine if someone is healthy enough to participate and establish baseline values for monitoring safety during the trial.

While specific requirements vary by trial, patients generally need to have adequate bone marrow function, kidney function, and liver function to be eligible for studies testing chemotherapy or other systemic treatments. Documentation of these baseline values is essential because clinical trials carefully monitor for side effects, and comparing results to baseline helps identify any treatment-related problems.

Documentation of Prior Treatments

For patients with recurrent or metastatic EMC enrolling in clinical trials, detailed documentation of all previous treatments is required. This includes records of prior surgeries (with pathology reports and information about surgical margins), radiation therapy (including doses and treatment fields), and any chemotherapy or other systemic treatments received (with specific drug names, doses, and treatment durations).^[1]

This treatment history is crucial because many clinical trials exclude patients who have received certain prior therapies, while others specifically seek patients whose disease has progressed despite standard treatments. The goal is to ensure that the trial tests the new treatment in an appropriate patient population and that results can be interpreted correctly.

Prognosis and Survival Rate

Prognosis

The outlook for patients with extraskeletal myxoid chondrosarcoma varies considerably depending on whether the disease has spread at the time of diagnosis and other specific factors. Despite being a cancer, EMC is generally considered to have a relatively prolonged survival compared to many other sarcomas, though it carries significant risks of recurrence and metastasis over time.

For patients who present without metastases, the disease still carries substantial long-term risks. Studies have shown that approximately 37 percent of patients develop local recurrence, typically after a median time of 3.3 years following initial treatment. Additionally, about 26 percent of patients develop distant recurrence (metastasis to other parts of the body), with a median time to distant spread of 3.2 years.^[1] This means that even after successful initial treatment, careful long-term monitoring is essential because recurrence can happen years later.

About 13 percent of patients present with metastases already present at the time of initial diagnosis.^[1] Research has shown that disease-specific survival is significantly shorter in patients who have distant metastasis at presentation compared to those who do not.^[11] However, even patients with metastatic disease can experience prolonged survival because EMC tends to progress slowly. Some patients have been documented surviving for several years with metastatic disease, remaining relatively asymptomatic even without aggressive treatment.^[13]

Several factors have been identified as affecting prognosis. Research indicates that the surgical margin status is a significant factor for local recurrence risk. Patients whose tumors were not completely removed (R1 or R2 surgical margins, meaning cancer cells remained at the edge of removed tissue) have a much higher risk of the cancer returning locally.^[11] Regarding overall survival, tumors located in the trunk of the body and larger tumor size have been identified as risk factors for unfavorable outcomes.^[11]

The long-term risk of metastasis remains high even many years after initial diagnosis. The disease has a tendency for late recurrence and spread, meaning patients require lifelong monitoring. However, when distant metastasis does occur, the progression is often gradual, allowing patients to live for several years. This indolent nature distinguishes EMC from many other cancers and influences treatment decisions, particularly regarding the use of chemotherapy in advanced disease.^[11]

Survival Rate

Long-term survival data for extraskeletal myxoid chondrosarcoma demonstrates that while this is a serious cancer, many patients can live for many years, even decades, following diagnosis. The 5-year overall survival rate has been reported at 82 percent, meaning that 82 out of 100 patients diagnosed with EMC are still alive five years after diagnosis. The 10-year overall survival rate is 65 percent, and the 15-year overall survival rate remains at 58 percent.^[1]

When looking specifically at disease-specific survival (death caused by the cancer rather than other causes), the rates are somewhat better. Studies have reported 1-year disease-specific survival at 92.3 percent, 5-year disease-specific survival at 83.1 percent, and 10-year disease-specific survival also at 83.1 percent.^[9] Another large study reported similar figures, with 1-year overall survival at 80 percent, 5-year at 72 percent, and 10-year at 72 percent.^[9]

Various studies have reported slightly different survival statistics, reflecting the rarity of this disease and differences in patient populations studied. The 5-year overall survival rates across different studies range from 71 to 100 percent, and 10-year overall survival rates range from 60 to 88 percent.^[11] The 5-year local recurrence-free survival (meaning no cancer returning at the original site) has been reported between 41 and 94 percent, while 10-year local recurrence-free survival ranges from 31 to 90 percent.^[11]

The rates of remaining free from distant metastasis are somewhat lower. The 5-year metastasis-free survival ranges from 64 to 73 percent, and the 10-year metastasis-free survival ranges from 35 to 69 percent.^[11] These numbers indicate that while many patients remain free from spread for years, the long-term risk of metastasis is substantial and continues even a decade after diagnosis.

It is important to understand that these statistics represent averages across many patients and cannot predict any individual person’s outcome. Survival depends on many factors including the stage at diagnosis, the location and size of the tumor, the completeness of surgical removal, and individual patient characteristics. The generally favorable survival rates compared to many other cancers reflect EMC’s typically slow growth pattern, though the disease requires lifelong monitoring due to the risk of late recurrence.

#1 Clinical Trials Search in Europe